These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 11019384)

  • 21. Mechanisms of carbapenem resistance in non-metallo-beta-lactamase-producing clinical isolates of Pseudomonas aeruginosa from a Tunisian hospital.
    Hammami S; Ghozzi R; Burghoffer B; Arlet G; Redjeb S
    Pathol Biol (Paris); 2009; 57(7-8):530-5. PubMed ID: 18977099
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential.
    Mushtaq S; Ge Y; Livermore DM
    Antimicrob Agents Chemother; 2004 Aug; 48(8):3086-92. PubMed ID: 15273124
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem.
    Sakyo S; Tomita H; Tanimoto K; Fujimoto S; Ike Y
    J Antibiot (Tokyo); 2006 Apr; 59(4):220-8. PubMed ID: 16830889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent updates of carbapenem antibiotics.
    El-Gamal MI; Brahim I; Hisham N; Aladdin R; Mohammed H; Bahaaeldin A
    Eur J Med Chem; 2017 May; 131():185-195. PubMed ID: 28324783
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates.
    El Amin N; Giske CG; Jalal S; Keijser B; Kronvall G; Wretlind B
    APMIS; 2005 Mar; 113(3):187-96. PubMed ID: 15799762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of 1 beta-methyl substituent and the basicity in C-2 side chain in carbapenem antibiotics on the activity against Pseudomonas aeruginosa oprD2 and nalB mutants.
    Sumita Y; Yamaga H; Sunagawa M
    J Antibiot (Tokyo); 1995 Jan; 48(1):89-91. PubMed ID: 7868397
    [No Abstract]   [Full Text] [Related]  

  • 27. A highly carbapenem-resistant Pseudomonas aeruginosa isolate with a novel blaVIM-4/blaP1b integron overexpresses two efflux pumps and lacks OprD.
    Maniati M; Ikonomidis A; Mantzana P; Daponte A; Maniatis AN; Pournaras S
    J Antimicrob Chemother; 2007 Jul; 60(1):132-5. PubMed ID: 17483142
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pseudomonas aeruginosa--a significant hospital pathogen and resistance to carbapenem].
    Kucisec-Tepes N
    Acta Med Croatica; 2004; 58(4):313-21. PubMed ID: 15700688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Antimicrobial susceptibility of Pseudomonas aeruginosa isolated in Fukushima Prefecture].
    Niitsuma K; Saitoh M; Kojimabara M; Kashiwabara N; Aoki T; Tomizawa M; Maeda J; Kosenda T
    Jpn J Antibiot; 2001 Feb; 54(2):79-87. PubMed ID: 11338681
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical review: balancing the therapeutic, safety, and economic issues underlying effective antipseudomonal carbapenem use.
    Slama TG
    Crit Care; 2008; 12(5):233. PubMed ID: 18983709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms.
    Jones RN; Sader HS; Fritsche TR
    Diagn Microbiol Infect Dis; 2005 May; 52(1):71-4. PubMed ID: 15878447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging strategies in infectious diseases: new carbapenem and trinem antibacterial agents.
    Sader HS; Gales AC
    Drugs; 2001; 61(5):553-64. PubMed ID: 11368281
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis, and SAR of novel carbapenem antibiotics with high stability to Xanthomonas maltophilia oxyiminocephalosporinase type II.
    Hakimelahi GH; Moosavi-Movahedi AA; Tsay SC; Tsai FY; Wright JD; Dudev T; Hakimelahi S; Lim C
    J Med Chem; 2000 Oct; 43(20):3632-40. PubMed ID: 11020277
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Comparison of antimicrobial use density (AUD) of carbapenem antibacterial agents and investigation of the drug susceptibility of Pseudomonas aeruginosa in 3 hospitals in southern Ibaraki Prefecture, Japan].
    Oishi T; Hitomi S; Kamoshita M; Fukue H; Kawahata D; Fukutake K
    Rinsho Byori; 2008 Jul; 56(7):570-6. PubMed ID: 18709988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multi-drug resistant Pseudomonas aeruginosa and Acinetobacter baumannii infections among hospitalized patients: risk factors and outcomes.
    Shanthi M; Sekar U
    J Assoc Physicians India; 2009 Sep; 57():636, 638-40, 645. PubMed ID: 20214000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of basic amino acids on susceptibility to carbapenems in clinical Pseudomonas aeruginosa isolates.
    Muramatsu H; Horii T; Morita M; Hashimoto H; Kanno T; Maekawa M
    Int J Med Microbiol; 2003 Jun; 293(2-3):191-7. PubMed ID: 12868655
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of multidrug-resistant and metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from a paediatric clinic in China.
    Dong F; Xu XW; Song WQ; Lü P; Yu SJ; Yang YH; Shen XZ
    Chin Med J (Engl); 2008 Sep; 121(17):1611-6. PubMed ID: 19024085
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The roles of active efflux system overexpression and outer membrane protein OprD deficiency or loss in carbapenem resistance of Pseudomonas aeruginosa].
    Yi MY; Wang PY; Huang HJ; Liu YC
    Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(7):457-62. PubMed ID: 16677571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contributions of IMP-10 metallo-beta-lactamase, the outer membrane barrier and the MexAB-OprM efflux system to high-level carbapenem resistance in Pseudomonas aeruginosa.
    Zhao WH; Hu Z; Chen G; Ito R; Hu ZQ
    Chemotherapy; 2009; 55(3):168-74. PubMed ID: 19420932
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined effects of the siderophore monosulfactam BAL30072 and carbapenems on multidrug-resistant Gram-negative bacilli.
    Hofer B; Dantier C; Gebhardt K; Desarbre E; Schmitt-Hoffmann A; Page MG
    J Antimicrob Chemother; 2013 May; 68(5):1120-9. PubMed ID: 23344577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.